Across TCGA pan-cancer cohorts, FOXI2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FOXI2 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in pheochromocytoma and paraganglioma (PCPG), where higher FOXI2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FOXI2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

PCPG, READ, and SKCM are the cancer types where FOXI2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PCPG	OS	Median	All	0.009	0.946	<.001	12	view →
READ	OS	Median	All	0.653	0.930	.004	6	view →
SKCM	DFS	Median	All	0.585	0.199	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: FOXI2 tumor-vs-normal RNA expression · all FOXI2 data types